These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 8961974)
21. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Chen S; Gomez SP; McCarley D; Mainwaring MG Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828 [TBL] [Abstract][Full Text] [Related]
22. Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma. Weintraub M; Revel-Vilk S; Charit M; Aker M; Pe'er J J Pediatr Hematol Oncol; 2007 Sep; 29(9):646-8. PubMed ID: 17805043 [TBL] [Abstract][Full Text] [Related]
23. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer. Yagita M; Ieki Y; Onishi R; Huang CL; Adachi M; Horiike S; Konaka Y; Taki T; Miyake M Int J Oncol; 1998 Jul; 13(1):91-6. PubMed ID: 9625808 [TBL] [Abstract][Full Text] [Related]
24. Drug-induced death of leukaemic cells after G2/M arrest: higher order DNA fragmentation as an indicator of mechanism. Sleiman RJ; Catchpoole DR; Stewart BW Br J Cancer; 1998; 77(1):40-50. PubMed ID: 9459144 [TBL] [Abstract][Full Text] [Related]
26. Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive oxygen species. Papież MA; Krzyściak W; Szade K; Bukowska-Straková K; Kozakowska M; Hajduk K; Bystrowska B; Dulak J; Jozkowicz A Drug Des Devel Ther; 2016; 10():557-70. PubMed ID: 26893544 [TBL] [Abstract][Full Text] [Related]
27. Exposure and schedule dependency of etoposide in neuroblastoma and leukaemia cells in vitro. Lowis SP; Newell DR; Pearson AD Eur J Cancer; 1995; 31A(4):622-6. PubMed ID: 7576982 [TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukemia with t(11;19)(q23;p13) developing in an adult T-cell leukemia patient treated with combined chemotherapy including etoposide. Kanemura N; Tsurumi H; Hara T; Yamada T; Sawada M; Naito T; Moriwaki H Int J Hematol; 2001 Dec; 74(4):475-6. PubMed ID: 11794709 [No Abstract] [Full Text] [Related]
29. Inhibition of etoposide (VP-16)-induced DNA recombination and mutant frequency by Bcl-2 protein overexpression. Hashimoto H; Chatterjee S; Berger NA Cancer Res; 1995 Sep; 55(18):4029-35. PubMed ID: 7664276 [TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. Pui CH; Ribeiro RC; Hancock ML; Rivera GK; Evans WE; Raimondi SC; Head DR; Behm FG; Mahmoud MH; Sandlund JT N Engl J Med; 1991 Dec; 325(24):1682-7. PubMed ID: 1944468 [TBL] [Abstract][Full Text] [Related]
31. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity. Qiu J; Catapano CV; Fernandes DJ Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211 [TBL] [Abstract][Full Text] [Related]
32. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096 [TBL] [Abstract][Full Text] [Related]
33. Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia. Yang J; Bogni A; Cheng C; Bleibel WK; Cai X; Fan Y; Yang W; Rocha JC; Pei D; Liu W; Dolan ME; Pui CH; Relling MV Clin Pharmacol Ther; 2008 Dec; 84(6):691-7. PubMed ID: 18509329 [TBL] [Abstract][Full Text] [Related]
34. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line. Patel S; Austin CA; Fisher LM Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515 [TBL] [Abstract][Full Text] [Related]
35. Human trithorax gene rearrangements in therapy-related acute leukaemia after etoposide treatment. Bower M; Parry P; Gibbons B; Amess J; Lister TA; Young BD; Evans GA Leukemia; 1994 Feb; 8(2):226-9. PubMed ID: 8309246 [TBL] [Abstract][Full Text] [Related]
36. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057 [TBL] [Abstract][Full Text] [Related]
37. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells. Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155 [TBL] [Abstract][Full Text] [Related]
38. Quantification of hprt gene deletions mediated by illegitimate V(D)J recombination in peripheral blood cells of humans. Fuscoe JC; Vira LK; Collard DD; Moore MM Environ Mol Mutagen; 1997; 29(1):28-35. PubMed ID: 9020304 [TBL] [Abstract][Full Text] [Related]
39. V(D)J recombinase-mediated HPRT mutations in peripheral blood lymphocytes of normal children. Finette BA; Poseno T; Albertini RJ Cancer Res; 1996 Mar; 56(6):1405-12. PubMed ID: 8640832 [TBL] [Abstract][Full Text] [Related]
40. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines. Ramilo-Torno LV; Avramis VI Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]